Brainalyze

Purpose: To revolutionize dementia treatment and care through a low-cost, 5-minute blood test that detects and distinguishes all major forms of dementia early Vision: To pioneer the first global dementia screening program using the Brainalyze blood test ________________________________________ Breakthrough innovation MX-Raman™: Proprietary platform technology that combines optical ‘fingerprinting’ + interpretable AI • Multiple lasers excite Raman scattering to create an optically-generated biochemical ‘fingerprint’ • AI uses optical fingerprint data for classification and prediction analysis • Only platform capable of broad-spectrum dementia detection and differentiation • 5-minute test | Costs <10% of current tests | Portable & scalable ________________________________________ USP • Beyond biomarkers: Competing blood tests (e.g. pTau217) detect only Alzheimer’s. MX-Raman detects and differentiates all major dementias • Simple single-step test: No reagents, antibodies, dyes required nor complex infrastructure, sophisticated equipment. Does not involve multiple steps unlike current tests. • Speed, cost and size: 100x faster and <10% of the costs of existing tests (imaging or biomarker based), <1m2 footprint • Versatile use cases: Early screening, patient triage, differential diagnosis, treatment monitoring, clinical trial stratification and companion diagnosis ________________________________________ IP & Defensibility • Patent pending in UK, EU, US (PCT/GB2022/053117) covering method, device and use cases • Proprietary and unique spectral database, AI analysis models, know-how and trade-secrets • Technology developed through 12 years of academic research ________________________________________ Progress to Date • Funding: $1.8M translational research funding already available • Clinical feasibility and traction: >400 patient samples tested, published 93%+ diagnostic accuracy, >1200 patient samples further secured • Device: Prototype and AI analysis models developed